COVID-19: consider cytokine storm syndromes and immunosuppression

The Lancet

Volumn 395, Issue 10229, 2020, Pages 1033-1034

  Mehta, Puja ^a   McAuley, Daniel F ^d,e   Brown, Michael ^c   Sanchez, Emilie ^b   Tattersall, Rachel S ^f,g   Manson, Jessica J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

^f SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; CORTICOSTEROID; FERRITIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 2; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; CYTOKINE RELEASE SYNDROME; CYTOKINE STORM; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LETTER; MORTALITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RISK FACTOR; SEPSIS; BETACORONAVIRUS; COMPLICATION; IMMUNOLOGY; METABOLISM; PANDEMIC; PASSIVE IMMUNIZATION; PROCEDURES; VIRUS PNEUMONIA;

ANTIRHEUMATIC AGENTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; CYTOKINES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; PANDEMICS; PNEUMONIA, VIRAL; STEROIDS;

EID: 85082178624     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(20)30628-0     Document Type: Letter

References (11)

1. WHO. Coronavirus disease 2019 (COVID-19)situation report – 52. https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2, March 12, 2020. (Accessed 13 March 2020)
2. Ruan, Q, Yang, K, Wang, W, Jiang, L, Song, J, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med, 2020 published online March 3. DOI:10.1007/s00134-020-05991-x.
3. Ramos-Casals, M, Brito-Zeron, P, Lopez-Guillermo, A, Khamashta, MA, Bosch, X, Adult haemophagocytic syndrome. Lancet 383 (2014), 1503–1516.
4. Karakike, E, Giamarellos-Bourboulis, EJ, Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol, 10, 2019, 55.
5. Seguin, A, Galicier, L, Boutboul, D, Lemiale, V, Azoulay, E, Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest 149 (2016), 1294–1301.
6. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
7. Russell, CD, Millar, JE, Baillie, JK, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395 (2020), 473–475.
8. Shakoory, B, Carcillo, JA, Chatham, WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial. Crit Care Med 44 (2016), 275–281.
9. Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showprojen.aspx?proj=49409, Feb 13, 2020. (Accessed 6 March 2020)
10. Richardson, P, Griffin, I, Tucker, C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395 (2020), e30–e31.
11. Fardet, L, Galicier, L, Lambotte, O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 66 (2014), 2613–2620.